Oliver is an Investment Director at UKI2S. Specialising in high impact biology based investments he has managed the engineering biology fund since its inception in 2014. He has invested in a broad range of companies in sectors as diverse as therapeutic, agritech and clean biotech, all of which are using biology to make sustainable and highly novel products.
He sits on multiple boards and has overseen exits including the £85m sale of Quethera to Astellas. He is also a member of the Future Planet Capital ESG steering group.
Prior to joining UKI2S, Oliver worked at the venture fund Imperial Innovations as well as other roles in the industry. He has a background in strategy analysis and consultancy including roles in New York and has a masters from the University of Bristol and commenced a PhD in bioremediation at the University of Nottingham.
